Drug Trial Radar · NCT06541730
A Study Evulating DA-302168S Tablets in Overweight/Obese Subjects
Last checked: Nov 19, 2026Latest source record: Apr 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Aug 30, 2024
Primary completion
Jan 30, 2025
Study completion Jan 30, 2025
Sponsor
- Lead sponsor
- Chendu DIAO Pharmaceutical Group CO., LTD.Industry
- Sponsor type
- Industry
- First posted
- Aug 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of continuous oral administration of DA-302168S tablets for 28 days in overweight/obese subjects.
Conditions
- Overweight and Obesity
Interventions
DA-302168SDrug
Titration was used in this study, and the initial plan was to dose titration in cohort 1 (15 mg dose group). The titration regimen and titration dose for subsequent cohorts will be determined based on the results of cohort 1, including the starting dose of titration, frequency of administration, and titration amplitude.
Placebo of DA-302168SDrug
Titration was used in this study, and the initial plan was to dose titration in cohort 1 (15 mg dose group). The titration regimen and titration dose for subsequent cohorts will be determined based on the results of cohort 1, including the starting dose of titration, frequency of administration, and titration amplitude.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Through study completion, an average of 49 days.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.